Rotavirus kills more than 400,000 young children a year, mostly in poor countries. In the United States, good medical care usually keeps it from being fatal, but it used to cause as many as 1 in 10 hospitalisations of young kids.
The first rotavirus vaccine came out in 1998 but was withdrawn a year later after it was linked to intussusception, a rare and serious twisted bowel condition. Doctors hoped that two newer versions Merck's RotaTeq and GlaxoSmithKline's Rotarix, which came out in 2006 and 2008 would avoid that problem.
One, led by Harvard University researchers, looked at nearly 1.4 million doses of either of the new vaccines given to babies in three large health plans. Researchers estimate there would be one to two extra cases of the bowel problem beyond what occurs naturally for every 100,000 recipients of the first dose. (Two or three doses are given, depending on which vaccine is used, starting around 2 months of age).
Both estimates are half or less of the number seen with the older vaccine.
"The rarity is striking," Dr Roger Glass of the Fogarty International Center at the National Institutes of Health said of the bowel problem under the new vaccines. "The benefits are tremendous compared to the risks."
He wrote a commentary accompanying the studies' publication.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
